Trial Profile
A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Oct 2015
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Sep 2011 Actual end date (June 2011) added as reported by ClinicalTrials.gov.
- 12 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.